Search hospitals > Texas > Conroe
Houston Methodist The Woodlands Hospital
Claim this profileConroe, Texas 77385
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Serous Cystadenocarcinoma
19 reported clinical trials
14 medical researchers
Summary
Houston Methodist The Woodlands Hospital is a medical facility located in Conroe, Texas. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Serous Cystadenocarcinoma and other specialties. Houston Methodist The Woodlands Hospital is involved with conducting 19 clinical trials across 63 conditions. There are 14 research doctors associated with this hospital, such as Jun Zhang, Aparna Kamat, MD, Eric Bernicker, MD, and Siddhartha Ganguly.Area of expertise
1Cancer
Stage IV
Stage III
HER2 positive
2Lung Cancer
Stage IV
Stage II
Stage III
Top PIs
Jun ZhangHouston Methodist Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
26 reported clinical trials
41 drugs studied
Aparna Kamat, MDHouston Methodist Sugar Land Hospital7 years of reported clinical research
Studies Ovarian Cancer
Studies Serous Cystadenocarcinoma
6 reported clinical trials
16 drugs studied
Eric Bernicker, MDHouston Methodist Hospital10 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
9 drugs studied
Siddhartha GangulyHouston Methodist Hospital1 year of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
5 reported clinical trials
9 drugs studied
Clinical Trials running at Houston Methodist The Woodlands Hospital
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
Multiple Myeloma
Plasma Cell Neoplasms
ALK Gene Rearrangement
Lung Carcinoma
Squamous Cell Carcinoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Houston Methodist The Woodlands Hospital?
Houston Methodist The Woodlands Hospital is a medical facility located in Conroe, Texas. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Serous Cystadenocarcinoma and other specialties. Houston Methodist The Woodlands Hospital is involved with conducting 19 clinical trials across 63 conditions. There are 14 research doctors associated with this hospital, such as Jun Zhang, Aparna Kamat, MD, Eric Bernicker, MD, and Siddhartha Ganguly.